Xenon pharmaceuticals inc. (XENE)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating activities:
Net loss

-41,595

-34,497

-30,704

-

-

-

-

-

Net loss

-

-

-

-22,997

-15,752

13,018

12,032

-4,301

Items not involving cash:
Depreciation

429

586

649

864

1,038

738

705

786

Amortization of discount on term loan

525

284

11

-

-

-

-

-

Deferred income tax recovery

-133

-105

-

-

-

-

-

-

Gain on write-off of assets

-

-

-

-

-

-

11

-1,030

Stock-based compensation

2,924

2,625

2,236

2,161

3,729

760

575

406

Non-cash compensation on issuance of subscription rights

-

-

-

-

-

-

73

8

Interest accrued on note payable

-

-

-

-

-

-

-

77

Deferred tenant inducements

-

-

-

-

-

-66

-115

183

Unrealized foreign exchange (gain) loss

302

-646

1,474

1,300

-6,902

-72

-94

34

Gain on termination of collaboration agreement (note 13c)

-

4,398

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

653

-280

232

-121

107

-209

76

-11,230

Prepaid expenses and other current assets

820

928

-613

-571

1,214

573

14

-162

Prepaid expenses, long term

-

-

-178

-686

1,094

-

-

-

Accounts payable and accrued expenses

4,541

783

-3

484

17

518

-228

540

Deferred revenue

30,452

-

-

-

-

-

-

-

Net cash used in operating activities

-4,632

-34,724

-28,726

-

-

-

-

-

Investing activities:
Deferred revenue

-

-

-

-157

-11,622

-14,410

-16,357

35,486

Net cash used in operating activities

-

-

-

-19,567

-18,103

266

-3,322

45,573

Purchases of property, plant and equipment

1,240

507

315

279

551

1,529

156

526

Sale of property, plant and equipment

-

-

-

-

-

-

10

7

Purchase of marketable securities

140,494

77,002

28,007

47,563

-

15,254

17,876

-

Proceeds from marketable securities

75,443

48,522

52,616

-

10,745

13,539

6,550

1,010

Net cash used in investing activities

-66,291

-28,987

24,294

-

-

-

-

-

Financing activities:
Net cash provided by investing activities

-

-

-

-47,842

10,194

-3,244

-11,472

491

Proceeds from issuance of refinanced term loan, net of issuance costs (note 10)

-

8,453

6,893

-

-

-

-

-

Issuance of common shares, net of issuance costs (note 11a)

27,396

102,850

-

23,832

-

42,644

49

-

Note payable

-

-

-

-

-

-

1,701

-

Deferred financing fees

-

-

-

-

-

1,533

2,739

-

Issuance of common shares pursuant to exercise of stock options

122

288

177

132

278

13

-

-

Net cash provided by financing activities

27,518

111,591

7,070

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

406

-612

-

-

-

-

-

-

Increase (decrease) in cash and cash equivalents

-42,999

47,268

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

23,964

278

41,124

-4,391

-

Effect of exchange rate changes on cash and cash equivalents

-

-

753

1,889

-5,744

-4,070

-3,027

170

Increase (decrease) in cash and cash equivalents

-

-

3,391

-41,556

-13,375

34,076

-22,212

46,234

Supplemental disclosures:
Interest paid

917

561

-

-

-

-

-

-

Interest paid

-

-

-

-

-

-

201

-

Interest received

2,216

1,067

740

341

659

574

279

-

Cash paid for operating lease

634

624

-

-

-

-

-

-

Interest received

-

-

-

-

-

-

-

170

Supplemental disclosures of non-cash transactions:
Fair value of stock options and warrants exercised on a cashless basis

719

1,125

25

-

-

-

-

-

Issuance of preferred shares in exchange for common shares (note 11d)

-

21,825

-

-

-

-

-

-

Issuance of common shares on conversion of subscription rights

-

-

-

-

-

124

45

22

Financing fees included in accounts payable and accrued liabilities

-

-

-

-

-

39

-

-

Fair value of options exercised on a cashless basis

-

-

-

404

744

-

-

-

Conversion of preferred shares to common shares (note 11d)

-

14,093

-

-

-

102,488

-

-

Teva Pharmaceuticals International GmbH and Teva Canada Limited [Member]
Termination of Teva agreement through cancellation of common shares (note 13c)

-

4,470

-

-

-

-

-

-